EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

QR Code

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Aim. To present the results of treatment with macitentan of patients included in the clinical trial SERAPHIN in Almazov National Medical Research Centre and define target therapy of pulmonary arterial hypertension (PAH) in real clinical practice.Material and methods. The article presents the results...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. A. Simakova, N. S. Goncharova, E. V. Karelkina, O. M. Moiseeva
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2018-04-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	pulmonary arterial hypertension endothelin receptor antagonists macitentan seraphin
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/802
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS
by: T. V. Martynyuk, et al.
Published: (2017-06-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

CLINICAL CASE OF COMBINATION THERAPY INCLUDING AMBRIZENTAN IN THE PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: G. A. Movsisyan, et al.
Published: (2017-06-01)

AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM
by: T. V. Martynuk, et al.
Published: (2014-03-01)

CASE REPORT: THE POSSIBILITY OF SPECIFIC THERAPY OPTIMIZATION BY SWITCHING FROM BOSENTAN TO MACITENTAN IN A PATIENT WITH CONGENITAL HEART DISEASE AND EISENMENGER SYNDROME
by: S. Ye. Gratsianakaya, et al.
Published: (2018-03-01)

New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations
by: T. V. Martynyuk, et al.
Published: (2010-04-01)

CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

Shear Stress-Dependent Modulation of Endothelin B Receptor: The Role of Endothelial Glycocalyx Heparan Sulfate
by: Camden Holm, et al.
Published: (2025-07-01)

TACTICS FEATURES OF CONDUCTING AND CHOOSING SPECIFIC THERAPY FOR ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE
by: O. A. Arkhipova, et al.
Published: (2018-03-01)

MACITENTAN: THE EVOLUTION OF THE CLASS ENDOTHELIN RECEPTOR ANTAGONISTS TO IMPROVE EFFICACY AND SAFETY OF PAH TREATMENT
by: T. V. Martynuk, et al.
Published: (2013-06-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

NEW OPPORTUNITIES PATHOGENETIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynuk, et al.
Published: (2013-03-01)

Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place
by: L. I. Olbinskaya, et al.
Published: (2007-02-01)

CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
by: E. A. Devetyarova, et al.
Published: (2018-06-01)

THE ROLE OF ENDOTHELIN-1 IN VASCULAR HEMOSTASIS OF PERIODONTAL TISSUES
by: N.V. Yarychkivska
Published: (2018-03-01)

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
by: S. A. Boytsov, et al.
Published: (2016-01-01)

Hereditary features of plasma concentrations of endothelin-1 in men with hypertension and chronic heart failure
by: H. O. Palahniuk, et al.
Published: (2016-12-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

EFFECTS OF CALCIUM ANTAGONISTS OF THE THIRD GENERATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND CONCOMITANT CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: D. A. Yakhontov, et al.
Published: (2016-01-01)

2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION
by: Nazzareno Galiè, et al.
Published: (2016-05-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

EXPRESSION OF PATTERN-RECOGNIZING RECEPTORS AND TRANSCRIPTIONAL REGULATORS OF T HELPER CELL DIFFERENTIATION BY INTESTINAL LYMPHOCYTES IN EXPERIMENTAL ILEITIS AND UPON ADMINISTRATION OF SIMVASTATIN AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
by: A. S. Zherebiatiev, et al.
Published: (2015-04-01)

Endothelial functional activity and circadian blood pressure dynamics in hypertensive patients treated with angiotensin receptor antagonists
by: N. G. Poteshkina, et al.
Published: (2011-10-01)

NMDA receptors antagonists alleviated the acute phase of traumatic brain injury
by: Mehrdad Hajinejad, et al.
Published: (2025-02-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
by: E. M. Khurs, et al.
Published: (2016-01-01)

Ultrastructural changes of platelet granules in patients with type 2 diabetes mellitus and hypertension in applying of angiotensin II receptor antagonists
by: Pertseva N.O.
Published: (2016-06-01)

ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: ADVANTAGES OF CALCIUM ANTAGONISTS
by: T. V. Adasheva, et al.
Published: (2016-01-01)

CLINICAL CASE: COMBINATION THERAPY WITH BOSENTAN AND SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION
by: V. V. Bystrov, et al.
Published: (2014-12-01)

A TWO-YEAR STUDY OF CANCEROGENIC POTENTIAL OF THE NEW OPIOID RECEPTOR ANTAGONIST ONDELOPRAN IN RATS
by: K. L. Kryshen, et al.
Published: (2019-06-01)

ENDOTHELINES AND CARDIOVASCULAR PATHOLOGY
by: A. M. Alieva, et al.
Published: (2014-11-01)

Pharmacokinetics, Pharmacodynamic, Safety and Tolerability of Fazamorexant, a Novel Dual Orexin Receptor Antagonist: Report of the First-in-Human Study
by: Ni J, et al.
Published: (2025-06-01)

Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase‐5 Inhibitors (PDE5i)
by: Nicholas A. Kolaitis, et al.
Published: (2025-04-01)

NMDA receptor antagonist induced c-Fos expression in the medial entorhinal cortex during postnatal development
by: Feng Liang, et al.
Published: (2025-07-01)

Expression of endothelin in experimental myocardial infarction in a changed concentration of FGF and VEGF
by: M. G. Shurygin, et al.
Published: (2013-02-01)

Endothelin-1 level in the tear fluid of children with primary congenital glaucoma
by: L. A. Katargina, et al.
Published: (2023-03-01)

Effect of Curcumin on Nitric Oxide and Endothelin-1 Levels in L-NAME-Induced Preeclamptic Wistar Rat
by: Bambang Rahardjo, et al.
Published: (2024-12-01)

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study
by: Maria Beatrice Morelli, et al.
Published: (2025-07-01)

Left ventricular hypertrophy: prognostic value, pathogenesis, possible remodeling: focusing on angiotensin receptor antagonists
by: M. D. Smirnova, et al.
Published: (2007-12-01)